Why LIB Therapeutics’ lerodalcibep data matter for next-generation cholesterol care
Monthly PCSK9 therapy is getting crowded. LIB Therapeutics’ LEROCHOL data raise a sharper question on adherence, access and durability.
Is Arrowhead’s plozasiran becoming the RNAi drug to watch in extreme triglyceride disorders?
Arrowhead’s plozasiran data ease dosing concerns in complex patients, but Phase 3 results will decide its broader triglyceride market role.